| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
TSPP tetrasodium does not target a specific protein or enzyme. As a porphyrin derivative, its utility in research is based on its photophysical properties and ability to generate reactive oxygen species upon light irradiation.
|
|---|---|
| ln Vitro |
The in vitro activity of TSPP tetrasodium is characterized by its strong absorption in the visible region, with characteristic Soret and Q bands typical of porphyrins. The compound can act as a photosensitizer, generating reactive oxygen species upon light irradiation, which is valuable for photodynamic therapy research.
|
| ln Vivo |
TSPP tetrasodium is not used as a therapeutic agent. Its in vivo utility is limited to research applications involving photodynamic therapy and as a fluorescent probe. The compound is not intended for systemic therapeutic use.
|
| Enzyme Assay |
In vitro binding assays are not typically performed for TSPP tetrasodium as it functions as a photosensitizer and fluorescent probe rather than a drug targeting specific enzymes or receptors. The compound's interaction with light and its ability to generate reactive oxygen species can be studied using spectroscopic methods.
|
| Cell Assay |
For in vitro cellular experiments, TSPP tetrasodium can be used in photodynamic therapy studies. Cells are incubated with the compound and then irradiated with light to induce the generation of reactive oxygen species, leading to cellular damage. The effects can be assessed using cell viability assays.
|
| Animal Protocol |
In vivo animal experiments with TSPP tetrasodium may be performed in photodynamic therapy research. The compound is administered to animal models, followed by light irradiation at the target site. The therapeutic efficacy and safety of the treatment can be evaluated.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of TSPP tetrasodium have not been extensively characterized. The compound has a molecular weight of 1039.88 g/mol and is water-soluble. It should be stored under appropriate conditions, protected from light.
|
| Toxicity/Toxicokinetics |
Toxicological data for TSPP tetrasodium has not been systematically evaluated, as the compound is intended for research applications only and not for therapeutic use. Standard laboratory safety precautions should be observed.
|
| References |
|
| Additional Infomation |
TSPP tetrasodium is a water-soluble porphyrin derivative used as a photosensitizer in photodynamic therapy research and as a fluorescent probe. The compound has no clinical or therapeutic applications.
|
| Molecular Formula |
C44H26N4NA4O12S4
|
|---|---|
| Molecular Weight |
1022.92
|
| Exact Mass |
957.064
|
| CAS # |
39050-26-5
|
| PubChem CID |
135742710
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.607g/cm3
|
| LogP |
8.176
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
26
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
80
|
| Complexity |
1720
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC2=NC1=C(C3=CC=C(N3)C(=C4C=CC(=N4)C(=C5C=CC(N5)=C2C6=CC=C(C=C6)S(=O)(=O)[O-])C7=CC=C(C=C7)S(=O)(=O)[O-])C8=CC=C(C=C8)S(=O)(=O)[O-])C9=CC=C(C=C9)S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+]
|
| InChi Key |
STYHVYFZXMZUMU-UHFFFAOYSA-J
|
| InChi Code |
InChI=1S/C44H30N4O12S4.4Na.12H2O/c49-61(50,51)29-9-1-25(2-10-29)41-33-17-19-35(45-33)42(26-3-11-30(12-4-26)62(52,53)54)37-21-23-39(47-37)44(28-7-15-32(16-8-28)64(58,59)60)40-24-22-38(48-40)43(36-20-18-34(41)46-36)27-5-13-31(14-6-27)63(55,56)57;;;;;;;;;;;;;;;;/h1-24,45,48H,(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60);;;;;12*1H2/q;4*+1;;;;;;;;;;;;/p-4
|
| Chemical Name |
tetrasodium;4-[10,15,20-tris(4-sulfonatophenyl)-21,23-dihydroporphyrin-5-yl]benzenesulfonate;dodecahydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9776 mL | 4.8880 mL | 9.7759 mL | |
| 5 mM | 0.1955 mL | 0.9776 mL | 1.9552 mL | |
| 10 mM | 0.0978 mL | 0.4888 mL | 0.9776 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
